€63.95
1.92% yesterday
Xetra, Mar 21, 05:37 pm CET
ISIN
DE0005313704
Symbol
AFX
Index
Sector

Carl Zeiss Meditec Target price 2025 - Analyst rating & recommendation

Carl Zeiss Meditec Classifications & Recommendation:

Buy
41%
Hold
53%
Sell
6%

Carl Zeiss Meditec Price Target

Target Price €60.62
Price €63.95
Deviation
Number of Estimates 17
17 Analysts have issued a price target Carl Zeiss Meditec 2026 . The average Carl Zeiss Meditec target price is €60.62. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 7 Analysts recommend Carl Zeiss Meditec to buy, 9 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Carl Zeiss Meditec stock has an average upside potential 2026 of . Most analysts recommend the Carl Zeiss Meditec stock at Hold.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Sep '24 2025
Estimates
Revenue Billion € 2.07 2.18
1.11% 5.45%
EBITDA Margin 17.59% 17.80%
15.88% 1.18%
Net Margin 8.52% 7.05%
37.46% 17.22%

17 Analysts have issued a sales forecast Carl Zeiss Meditec 2025 . The average Carl Zeiss Meditec sales estimate is

€2.2b
Unlock
. This is
5.45% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
€2.3b 8.95%
Unlock
, the lowest is
€2.1b 0.01%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 €2.1b 1.11%
2025
€2.2b 5.45%
Unlock
2026
€2.3b 7.39%
Unlock
2027
€2.5b 8.54%
Unlock
2028
€2.7b 6.55%
Unlock
2029
€2.9b 7.60%
Unlock

16 Analysts have issued an Carl Zeiss Meditec EBITDA forecast 2025. The average Carl Zeiss Meditec EBITDA estimate is

€388m
Unlock
. This is
6.70% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
€452m 24.35%
Unlock
, the lowest is
€335m 7.92%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 €364m 16.82%
2025
€388m 6.70%
Unlock
2026
€449m 15.68%
Unlock
2027
€512m 14.10%
Unlock
2028
€563m 9.91%
Unlock
2029
€609m 8.27%
Unlock

EBITDA Margin

2024 17.59% 15.88%
2025
17.80% 1.18%
Unlock
2026
19.18% 7.75%
Unlock
2027
20.16% 5.11%
Unlock
2028
20.79% 3.13%
Unlock
2029
20.93% 0.67%
Unlock

13 Carl Zeiss Meditec Analysts have issued a net profit forecast 2025. The average Carl Zeiss Meditec net profit estimate is

€154m
Unlock
. This is
12.67% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
€178m 1.10%
Unlock
, the lowest is
€108m 38.81%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 €176m 38.15%
2025
€154m 12.67%
Unlock
2026
€201m 31.06%
Unlock
2027
€245m 21.80%
Unlock
2028
€313m 27.55%
Unlock
2029
€369m 17.87%
Unlock

Net Margin

2024 8.52% 37.46%
2025
7.05% 17.22%
Unlock
2026
8.61% 22.13%
Unlock
2027
9.66% 12.20%
Unlock
2028
11.56% 19.67%
Unlock
2029
12.67% 9.60%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Sep '24 2025
Estimates
Earnings Per Share 2.01 1.76
38.15% 12.44%
P/E 36.43
EV/Sales 2.86

13 Analysts have issued a Carl Zeiss Meditec forecast for earnings per share. The average Carl Zeiss Meditec EPS is

€1.76
Unlock
. This is
12.44% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
€2.03 1.00%
Unlock
, the lowest is
€1.23 38.81%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 €2.01 38.15%
2025
€1.76 12.44%
Unlock
2026
€2.30 30.68%
Unlock
2027
€2.80 21.74%
Unlock
2028
€3.57 27.50%
Unlock
2029
€4.21 17.93%
Unlock

P/E ratio

Current 31.79 14.17%
2025
36.43 14.60%
Unlock
2026
27.80 23.69%
Unlock
2027
22.82 17.91%
Unlock
2028
17.89 21.60%
Unlock
2029
15.18 15.15%
Unlock

Based on analysts' sales estimates for 2025, the Carl Zeiss Meditec stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.01 42.99%
2025
2.86 5.13%
Unlock
2026
2.66 6.88%
Unlock
2027
2.45 7.86%
Unlock
2028
2.30 6.15%
Unlock
2029
2.14 7.06%
Unlock

P/S ratio

Current 2.71 47.37%
2025
2.57 5.17%
Unlock
2026
2.39 6.88%
Unlock
2027
2.20 7.87%
Unlock
2028
2.07 6.15%
Unlock
2029
1.92 7.06%
Unlock

Current Carl Zeiss Meditec Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HAUCK AUFHAEUSER INVESTMENT BANKING
Locked
Locked
Locked Jan 05 2025
DZ BANK
Locked
Locked
Locked Dec 18 2024
METZLER EQUITIES
Locked
Locked
Locked Dec 17 2024
EQUITA SIM
Locked
Locked
Locked Dec 15 2024
LANDESBANK BADEN-WUERTTEMBERG
Locked
Locked
Locked Dec 15 2024
EQUI.TS
Locked
Locked
Locked Dec 12 2024
MWB RESEARCH AG
Locked
Locked
Locked Dec 11 2024
Analyst Rating Date
Locked
HAUCK AUFHAEUSER INVESTMENT BANKING:
Locked
Locked
Jan 05 2025
Locked
DZ BANK:
Locked
Locked
Dec 18 2024
Locked
METZLER EQUITIES:
Locked
Locked
Dec 17 2024
Locked
EQUITA SIM:
Locked
Locked
Dec 15 2024
Locked
LANDESBANK BADEN-WUERTTEMBERG:
Locked
Locked
Dec 15 2024
Locked
EQUI.TS:
Locked
Locked
Dec 12 2024
Locked
MWB RESEARCH AG:
Locked
Locked
Dec 11 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today